Dilantin Shortage Update: What Patients Need to Know in 2026

Dilantin (phenytoin) has been on and off shortage lists since at least 2011. If you're a patient managing epilepsy with this medication, understanding the current supply situation and how to protect yourself is critical. This guide provides the most up-to-date patient-focused summary of the Dilantin shortage in 2026.

The Current Shortage Status in 2026

Here is the current status by formulation:

Extended-release capsules (100 mg, 30 mg): Generally available from multiple manufacturers, but intermittent spot shortages with specific suppliers continue to affect patients in certain regions. If your usual brand isn't available, a different manufacturer's version may be in stock nearby.

Oral suspension (Dilantin-125, 125 mg/5 mL): This formulation faced significant back-order issues through 2025. Viatris estimated a mid-2025 restoration, but supply remains tight heading into 2026. Sun Pharma also had the suspension on back-order with no estimated release date.

Injectable phenytoin (50 mg/mL): The injection shortage that began in December 2022 was largely resolved by August 2025 when Hikma's 5 mL vials became consistently available. Acella also has injectable phenytoin available.

Chewable tablets (Infatabs, 50 mg): Availability varies. Check with your pharmacy and ask specifically for this formulation if that's what your prescription requires.

A Brief Timeline of Dilantin Shortages

2011: Pfizer announced a Dilantin 30 mg capsule shortage due to a manufacturing issue. Resolution was expected by June 2011.

December 2022: Phenytoin sodium injection entered an ASHP-listed shortage as Hikma experienced supply disruptions.

2023–2024: Viatris discontinued its 240 mL oral suspension bottles. Demand shifted to extended-release capsules and the smaller Dilantin-125 suspension, creating supply pressure.

May 2025: Dilantin-125 oral suspension (125 mg/5 mL) formally listed as in shortage on ASHP. Both Viatris and Sun Pharma products affected.

August 2025: Injectable phenytoin shortage resolved.

2026: Extended-release capsules broadly available with intermittent regional spot shortages. Oral suspension supply remains unpredictable.

Why Does This Matter More With Phenytoin Than Other Drugs?

With most medications, a shortage is a nuisance. With phenytoin, it's a patient safety issue. Here's why:

Narrow therapeutic index (NTI): The effective blood level range is narrow (10–20 mcg/mL). Switching manufacturers or formulations can alter drug absorption enough to cause breakthrough seizures or toxicity.

No emergency self-substitution: Unlike, say, an antibiotic, you can't skip doses or take a "similar" medication from your medicine cabinet as a bridge.

Driving and safety: A breakthrough seizure can have serious legal and safety consequences, including loss of driving privileges.

What Can Patients Do Right Now?

Don't wait until you're out of medication to start searching. Start looking 2–3 weeks before your next fill is due.

Use medfinder to find which pharmacies near you have your specific formulation in stock.

Talk to your neurologist about a contingency plan — what formulation or manufacturer is acceptable as a backup, and whether a switch requires blood level monitoring.

Ask if you qualify for a 90-day supply. Insurance plans and many pharmacies can dispense 90-day supplies, which creates a buffer.

Ask your neurologist to write 'DAW' (Dispense As Written) with the preferred manufacturer specified if you must stay on a specific product.

Is There a Permanent Solution?

For patients with persistent supply issues, transitioning to an alternative medication may be an option. This is a complex medical decision that must involve your neurologist. Read our guide on Alternatives to Dilantin for more detail on what your doctor may consider.

For now, the most practical approach is proactive supply management: plan ahead, check multiple pharmacies, and use tools like medfinder to locate your medication before you run out.